Abstract 1925
Background
Limited researches evaluate effectiveness of cancer patients-centered home care management. In this context, patients’ needs rather than prognosis should be considered. Our project represents an opportunity for patients who may benefit from chemotherapy, but with physical and social problems that prevent day-hospital access, and a model of no profit contribution to the Public Health System.
Methods
Our Medical Oncology Department, supported by a no-profit organization and according to the GP, conducted the project from May 2014 to March 2019. We included frail patients selected with G8 score (<14), with advanced disease, treated with oral, subcutaneously or parenteral biological agents, with limitations to day-hospital access, comorbidities and at least six months life expectancy. A multidisciplinary team, coordinated by three oncologists, included also four nurses, a pain therapist, a psychologist and a physiotherapist. Satisfaction was evaluated with the FAMCARE scale.
Results
A total of 161 patients (median age of 71 years, range 38-93), were enrolled. Ninety percent of patients had metastatic disease and median G8 score of 8.8 (2.5-13.5). All of them received home cancer treatments and concomitant supportive cares, if necessary; 24 patients received two or more lines of cancer treatment. Considering 148 concluded taking care, median time was 175 days (7-1200). A median number of 254 (195-325) nursing home visits and 164 (139-190) medical home visits were performed each year, with an average of 1.6 and 1.1 visits per month per patient, respectively. Median number of in-line patients was 20 (17-25). Hospitalization occurred in 19.3%. Home blood transfusions were delivered in 6 patients, paracentesis in 8. One third of them died at home. FAMECARE assessed high satisfaction.
Conclusions
Our experience demonstrates that the integration of home cancer treatment and supportive care is feasible and effective. Hospitalization rate is lower than data reported in literature. If confirmed in perspective pharmaco-economics studies, our data suggest that home cancer treatments provide high quality assistance to frail patients. Integration with no-profit organization was successful. Our model could be applied in other settings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2490 - Gender effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of anamorelin (ANAM) in healthy volunteers and cancer patients with cachexia
Presenter: Stein Kaasa
Session: Poster Display session 1
Resources:
Abstract
4294 - The Patient Voice: An Irish Survey of Nutrition Attitudes & Access to Dietetic Care Throughout the Cancer Journey
Presenter: Erin Stella Sullivan
Session: Poster Display session 1
Resources:
Abstract
4701 - Treatment-related adverse events and tolerability in patients with advanced non-squamous non-small cell lung cancer treated with first-line checkpoint inhibitors in combination with chemotherapy
Presenter: Ruth D'cunha
Session: Poster Display session 1
Resources:
Abstract
2985 - Clinical utility of a systematic toxicity assessment form (STAF) in patients with breast cancer receiving adjuvant or neoadjuvant therapy.
Presenter: Jwa Hoon Kim
Session: Poster Display session 1
Resources:
Abstract
2358 - Physicians’ satisfaction with Health-related quality of life (HRQoL) assessment in daily clinical practice using electronic patient-reported outcome (ePRO) for cancer patients.
Presenter: Guillaume Mouillet
Session: Poster Display session 1
Resources:
Abstract
5172 - Predictors of Survival in Patients with Incurable Cancer
Presenter: Erin Stella Sullivan
Session: Poster Display session 1
Resources:
Abstract
2281 - Patients and Physicians' Satisfaction with Telemedicine (TM) in Cancer Care and Factors that Correlate with a Positive Patient’s Experience
Presenter: Hurria Gondal
Session: Poster Display session 1
Resources:
Abstract
2193 - Adherence to ESMO 2014 guidelines on bone-targeting agent (BTA) initiation for breast and prostate cancer patients: real-world insights from practicing European physicians
Presenter: Alex Rider
Session: Poster Display session 1
Resources:
Abstract
2200 - Use of skeletal-related events preventive agents in patients with solid tumours and bone metastases in central Denmark
Presenter: Anders Boysen
Session: Poster Display session 1
Resources:
Abstract
2504 - Inadequacy of current definition and staging system of Medication-Related Osteonecrosis of Jaw (MRONJ) released by AAOMS : a Computed Tomography study in 151 cancer and myeloma patients
Presenter: Vittorio Fusco
Session: Poster Display session 1
Resources:
Abstract